Novo Nordisk Patent Suit Over Prandin Nixed

Law360, New York (April 1, 2010, 12:59 PM EDT) -- Mylan Pharmaceuticals Inc. has won its bid to dismiss a patent infringement suit brought by Novo Nordisk A/S over a generic version of diabetes drug Prandin.

Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey on Wednesday granted Mylan's motion to dismiss, ruling that the defendant was not seeking to practice the part of the patent over which Novo sued.

The U.S. Food and Drug Administration approved Novo's sale of repaglinide, branded as Prandin, for use in the treatment of...
To view the full article, register now.